How do you view the lack of current safety signals encountered in CV outcome trials with PCSK9 inhibitors? What are the implications for lifelong use of these agents?

How do you view the lack of current safety signals encountered in CV outcome trials with PCSK9 inhibitors? What are the implications for lifelong use of these agents?

CLICK HERE FOR CME CREDIT

How do you view the lack of current safety signals encountered in CV outcome trials with PCSK9 inhibitors? What are the implications for lifelong use of these agents?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

R. Scott Wright, MD

R. Scott Wright, MD

Professor of Medicine Department of Cardiovascular Medicine Cardiovascular Division Mayo Clinic